Nestin and WT-1: Potential Interplay in Astrocytoma Tumor Biology
DOI:
https://doi.org/10.63623/1ey3hk73Keywords:
Astrocytoma, Nestin, WT-1, Tumor grade, Prognosis, ImmunoexpressionAbstract
Background: Glial cells are the origin of gliomas, a diverse group of brain tumors including Astrocytoma, Oligodendrogliomas and Ependymoma, classified based on their cellular origin. The St. Anne/Mayo grading system evaluates key histological features such as necrosis, endothelial proliferation, mitotic activity and cellular atypia to determine tumor grade and guide treatment. Although less common than other cancers, CNS malignancies cause significant morbidity and mortality, with thousands of new cases and deaths reported annually worldwide. Objective: The purpose of the current study was to examine the relationship between immunoexpression of the Nestin protein and WT-1 gene and various grades of Astrocytoma. Methods: A cross-sectional study was carried out at the Pathology Department of Basic Medical Science Institutes, Jinnah Postgraduate Medical College in Karachi, Sindh, Pakistan, from January 2019 to December 2022. There were 60 Astrocytoma cases in this investigation. All the cases of various grades of Astrocytoma were received in the department of Pathology, Basic Medical Sciences Institute, Jinnah Post Graduate Medical Center, Karachi were deeply reviewed and were included in this study. Results: Sixty examples of Astrocytoma were immunostained with WT-1 and Nestin. 86.7% of Astrocytoma cases had Nestin positivity, while 93.3% had positive WT-1 immunostaining. It was shown that there was a significant association (p<0.001) between the score of the both immunomarker Nestin and WT-1 and the grade of the tumor, with a higher score for high-grade (grade III and grade IV) and a lower score for low-grade (grade I and grade II) Astrocytoma. Conclusion: Nestin and WT1 immunoexpression is positively correlated with higher tumor grade and enhanced mitotic activity, suggesting that they may be useful prognostic indicators in Astrocytoma. Additionally, their strong association with tumor aggressiveness highlights Nestin and WT1's potential as therapeutic targets as well as prognostic factors, opening the door to more individualize and efficient Astrocytoma management treatment plans.
References
[1]Kapoor M, Gupta V. Astrocytoma. In: StatPearls [Internet]. StatPearls Publishing, 2021.
[2]Rifat Abdel-Maqsoud Mohamed R, Yousef Ali M. Expression of p53 and Ki-67 in different grades of astrocytomas. International Journal of Medical Arts, 2022, 4(7), 2494-24502.
[3]Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians, 2021, 71(3), 209-249. DOI: 10.3322/caac.21660
[4]Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Science, 2015, 106(7), 803-811. DOI: 10.1111/cas.12691
[5]Potokar M, Morita M, Wiche G, Jorgačevski J. The diversity of intermediate filaments in astrocytes. Cells, 2020, 9(7), 1604. DOI: 10.3390/cells9071604
[6]Szymańska-Chabowska A, Świątkowski F, Jankowska-Polańska B, Mazur G, Chabowski M. Nestin expression as a diagnostic and prognostic marker in colorectal cancer and other tumors. Clinical Medicine Insights: Oncology, 2021, 15:11795549211038256. DOI: 10.1177/11795549211038256
[7]Yamagishi A, Susaki M, Takano Y, Mizusawa M, Mishima M, Iijima M, et al. The structural function of nestin in cell body softening is correlated with cancer cell metastasis. International Journal of Biological Sciences, 2019, 15(7), 1546. DOI: 10.7150/ijbs.33423
[8]Akramov NR, Shavaliev RF, Osipova IV. New mutation in WT1 gene in a boy with an incomplete form of Denys-Drash syndrome: A CARE-compliant case report. Medicine, 2021, 100(19), e25864. DOI: 10.1097/MD.0000000000025864
[9]Pan X, Mengge G, Wang K, Wang Y, Kong J, Sun Y, et al. Prognostic impact of WT1 mutation on AML of different risk groups based on 2022 European Leukemianet (ELN) risk classification. Blood, 2022, 140(Supplement 1), 3216-3217. DOI: 10.1182/blood-2022-166323
[10]Ferrari M, Watanabe A, da Silva TE, Gomes NL, Batista RL, Nishi MY, et al. WT1 pathogenic variants are associated with a broad spectrum of differences in sex development phenotypes and heterogeneous progression of renal disease. Sexual Development, 2022, 16(1), 46-54. DOI: 10.1159/000517373
[11]Chen M, Cen C, Wang N, Shen Z, Wang M, Liu B, et al. The functions of Wt1 in mouse gonad development and somatic cells differentiation. Biology of Reproduction, 2022, 107(1), 269-274. DOI: 10.1093/biolre/ioac050
[12]Gülten G, Yalçın N, Baltalarlı B, Doğu G, Acar F, Doğruel Y. The importance of IDH1, ATRX and WT-1 mutations in glioblastoma. Polish Journal of Pathology, 2020, 71(2), 127-137. DOI: 10.5114/pjp.2020.97020
[13]Salvatorelli L, Calabrese G, Parenti R, Vecchio GM, Puzzo L, Caltabiano R, et al. Immunohistochemical expression of Wilms’ Tumor 1 protein in human tissues: from ontogenesis to neoplastic tissues. Applied Sciences, 2019, 10(1), 40. DOI: 10.3390/app10010040
[14]Kurdi M, Butt N S, Baeesa S, Kuerban A, Maghrabi Y, Bardeesi A et al. Sensitivity assessment of Wilms tumor gene (WT1) expression in glioblastoma using qPCR and immunohistochemistry and its association with IDH1 mutation and recurrence interval. Biologics: Targets and Therapy, 2021, 289-297. DOI: 10.2147/BTT.S323358
[15]Abdelkareem RM, Elnashar AT, Fadle KN, Muhammad EM. Immunohistochemical expression of nestin as cancer stem cell marker in gliomas. Journal of Neuroscience and Neurological Disorders, 2019, 3(2), 162-166. DOI: 10.29328/journal.jnnd.1001027
[16]Woo CG. Clinicopathological significance of Nestin expression as a diagnostic and prognostic marker in brain gliomas, independent of IDH mutation. 2021. DOI: 10.21203/rs.3.rs-994741/v1
[17]An S, Song IH, Woo CG. Diagnostic value of Nestin expression in adult gliomas. International Journal of Surgical Pathology, 2023, 31(6), 1014-1020. DOI: 10.1177/10668969221125792
[18]Rehfeld M, Matschke J, Hagel C, Willenborg K, Glatzel M, Bernreuther C. Differential expression of stem cell markers in proliferating cells in glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147(10), 2969-2982. DOI: 10.1007/s00432-021-03704-5
[19]Rushing EJ, Sandberg GD, Horkayne-Szakaly I. High-grade astrocytomas show increased Nestin and Wilms’s tumor gene (WT1) protein expression. International Journal of Surgical Pathology, 2010, 18(4), 255-259. DOI: 10.1177/1066896909338596
[20]Dahlrot RH, Hansen S, Schroeder HD, Jensen SS, Hjelmborg J, Kristensen BW. P04. 09: The prognostic potential of CD133 and nestin in a population-based cohort of glioma patients. Neuro-oncology, 2014, 16(Suppl 2), ii38. DOI: 10.1093/neuonc/nou174.141
[21]Hatanpaa KJ, Hu T, Vemireddy V, Foong C, Raisanen JM, Oliver D, et al. High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. Journal of Neuro-Oncology, 2014, 117:183-9. DOI: 10.1007/s11060-014-1376-7
[22]Manocha A, Jain S. WT1 in astrocytomas: Comprehensive evaluation of immunohistochemical expression and its potential utility in different histological grades. Indian Journal of Cancer, 2019, 56(3), 197-201. DOI: 10.4103/ijc.IJC_51_18
[23]Rauscher J, Beschorner R, Gierke M, Bisdas S, Braun C, Ebner FH, et al. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. Journal of Clinical Pathology, 2014, 67(7), 556-561. DOI: 10.1136/jclinpath-2013-202114
[24]Yokota C, Nakata J, Takano K, Nakajima H, Hayashibara H, Minagawa H, et al. Distinct difference in tumor-infiltrating immune cells between Wilms’ tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neuro-Oncology Advances, 2021, 3(1):vdab091. DOI: 10.1093/noajnl/vdab091
[25]Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka SI, Jomgeow T, et al. Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Science, 2004, 95(10), 822-827. DOI: 10.1111/j.1349-7006.2004.tb02188.x
[26]Oji Y, Hashimoto N, Tsuboi A, Murakami Y, Iwai M, Kagawa N, et al. (2016). Association of WT-1 IgG antibody against WT-1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT-1 peptide. International Journal of Cancer, 2016, 139(6), 1391-1401. DOI: 10.1002/ijc.30182
[27]Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, et al. Diagnostic value of WT1 in neuroepithelial tumours. Neuropathology and Applied Neurobiology, 2009, 35(1), 69-81. DOI: 10.1111/j.1365-2990.2008.00957.x
[28]Bassam AM, Abdel-Salam LO, Khairy D. WT1 Expression in glial tumors: Its possible role in angiogenesis and prognosis. Academic Journal of Cancer Research, 2014, 7(2), 50-58. DOI: 10.5829/idosi.ajcr.2014.7.2.1109
[29]Mahzouni P, Meghdadi Z. WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index. Advanced Biomedical Research, 2013, 2(1), 33. DOI: 10.4103/2277-9175.108772
[30]Tong Z, Yin Z. Distribution, contribution and regulation of Nestin+ cells. Journal of Advanced Research, 2024, 61, 47-63. DOI: 10.1016/j.jare.2023.08.013
[31]Yokota C, Kagawa N, Takano K, Chiba Y, Kinoshita M, Kijima N, et al. Maintenance of WT1 expression in tumor cells is associated with a good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy. Cancer Immunology, Immunotherapy. 2022, 71(1), 189-201. DOI: 10.1007/s00262-021-02954-z
[32]Yuan B, Wang G, Tang X, Tong A, Zhou L. Immunotherapy of glioblastoma: Recent advances and future prospects. Human Vaccines & Immunotherapeutics, 2022, 18(5), 2055417. DOI: 10.1080/21645515.2022.2055417
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Asma Jalbani, Parisa Bashir, Prih Bashir, Javeria Tunio, Farah Siraj, Arpna Nihal
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
